Hillstream rockets on new data for ferroptosis candidate in NSCLC

11 February 2023
research_vials_biotech_big

US biotech Hillstream BioPharma (Nasdaq: HILS), which is developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, saw its shares skyrocket 75% to $2.07 pre-market on Friday, and still closed up 35% at $1.59, after it released new clinical data on its lead candidate HSB-216.

The company announced initial results evaluating the synergy of HSB-1216 with immune checkpoint inhibitors in KRAS G12C-mutated non-small cell lung cancer (NSCLC) cells, Calu-1, with pembrolizumab, the blockbuster anti-PD-1 antibody sold by Merck & Co (NYSE: MRK) under the trade name Keytruda.

The study demonstrated significantly greater tumor inhibition of Calu-1 cells, when grown with human PBMCs (SEB-activated) and treated with HSB-1216 and pembrolizumab.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology